The DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.
Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides
Open accessAbstract
Parkinson's disease is a progressive neurodegenerative disorder characterized by the degeneration of midbrain nigral dopaminergic neurons. Although its etiology remains unknown, the pathological role of several factors has been highlighted, namely oxidative stress, neuroinflammation, protein misfolding, and mitochondrial dysfunction, in addition to genetic predispositions. The current therapy is mainly symptomatic with l-DOPA aiming to replace dopamine. Novel therapeutic approaches are being investigated with the intention of influencing pathways leading to neuronal death and dysfunction. The present review summarizes three novel approaches, the use of which is promising in pre-clinical studies. Polyphenols have been shown to possess neuroprotective properties on account of their well-established antioxidative and anti-inflammatory actions but also due to their influence on protein misfolding and mitochondrial homeostasis. Within the amazing ancillary effects of antibiotics, their neuroprotective properties against neurodegenerative and neuroinflammatory processes are of great interest for the development of effective therapies against Parkinson's disease. Experimental evidence supports the potential of antibiotics as neuroprotective agents, being useful not only to prevent the formation of toxic α-synuclein oligomers but also to ameliorate mitochondrial dysfunction and neuroinflammation. Neuropeptides offer another approach with their diverse effects in the nervous system. Among them, pituitary adenylate cyclase-activating polypeptide, a member of the secretin/glucagon superfamily, has several advantageous effects in models of neurodegeneration, namely anti-apoptotic, anti-inflammatory and antioxidant actions, the combination of which offers a potent protective effect in dopaminergic neurons. Owing to their pleiotropic modes of action, these novel therapeutic candidates have potential in tackling the multidimensional features of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, beta-lactams (cephalosporin antibiotics) have been shown to be effective in the treatment and alleviation of ND symptoms and in the treatment of experimentally induced neurological disorders such as PD, AD, ALS, traumatic brain injury (TBI), epilepsy, cerebral ischemia, and neuropathy (84, 117, 118).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–306 of 306
Neuroprotective Effect of PACAP Against NMDA-Induced Retinal Damage in the Mouse
Endo, K., Nakamachi, T., Seki, T., et al. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9434-x · Cited by 62
Brown, D., Tamás, A., Reglődi, D., & Tizabi, Y. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0015-7 · Cited by 62
Self-citationTetracyclines and Prion Infectivity
Forloni, G., Salmona, M., Marcon, G., & Tagliavini, F. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/1871526510909010023 · Cited by 62
Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease
Zaminelli, T., Gradowski, R. W., Bassani, T. B., Barbiero, J. K., Santiago, R. M., Ferreira, D. M., Baggio, C. H., & Vital, M. A. B. F. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9467-y · Cited by 61
Wang, Y., Yu, H., Pu, X., & Du, G. (2013) · Molecules · doi:10.3390/molecules181214726 · Cited by 61
Park, J., Hong, J.-S., Lee, K.-S., Kim, H.-Y., Lee, J.-J., & Lee, S. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.08.009 · Cited by 61
Li, R., Liang, T., Xu, L., Zheng, N., Zhang, K., & Duan, X. (2013) · Brain Research · doi:10.1016/j.brainres.2013.05.046 · Cited by 60
D-Cycloserine: Agonist turned antagonist
Lanthorn, T. H. (1994) · Amino Acids · doi:10.1007/bf00813745 · Cited by 60
Small molecules interacting with α-synuclein: antiaggregating and cytoprotective properties
Marchiani, A., Mammi, S., Siligardi, G., Hussain, R., Tessari, I., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sanna, D., et al. (2013) · Amino Acids · doi:10.1007/s00726-013-1503-3 · Cited by 59
Wang, G., Pan, J., Tan, Y., Sun, X., Zhang, Y., Zhou, H., Ren, R., Wang, X., & Chen, S. (2008) · Neuropeptides · doi:10.1016/j.npep.2008.03.002 · Cited by 57
Chen, J. J., & Ly, A.-V. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050395 · Cited by 56
Bi, W., ZHU, L., Jing, X., Zeng, Z., Liang, Y., XU, A., Liu, J., Xiao, S., Yang, L., Shi, Q., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2480 · Cited by 56
Clinical trials of neuroprotection for Parkinson’s disease
LeWitt, P. A. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s23 · Cited by 55
Xu, J., Wei, C., Xu, C., Bennett, M. C., Zhang, G., Li, F., & Tao, E. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.074 · Cited by 55
Increased Stathmin1 Expression in the Dentate Gyrus of Mice Causes Abnormal Axonal Arborizations
Yamada, K., Matsuzaki, S., Hattori, T., Kuwahara, R., Taniguchi, M., Hashimoto, H., Shintani, N., Baba, A., Kumamoto, N., Yamada, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008596 · Cited by 54
Szabadfi, K., Atlasz, T., Kiss, P., et al. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9254-y · Cited by 54
Molecular mechanisms of the neuroprotective neurorescue action of multi-target green tea polyphenols
Mandel, S. A. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s286 · Cited by 54
Teraoka, M., Nakaso, K., Kusumoto, C., Katano, S., Tajima, N., Yamashita, A., Zushi, T., Ito, S., & Matsura, T. (2012) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.d-11-00030 · Cited by 53
Cuevas, C. M., Huenchuguala, S., Muñoz, P., Villa, M., Paris, I. B., Mannervik, B., & Segura‐Aguilar, J. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9500-1 · Cited by 53
Delgado, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00283-8 · Cited by 53
Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus
Sultan, S., Gebara, E., & Toni, N. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00131 · Cited by 53
Wang, A., Liou, Y., Pawlak, C. R., & Ho, Y. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.006 · Cited by 52
Lamine, A., Létourneau, M., Doan, N. D., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.014 · Cited by 51
Peroxynitrite as regulator of vascular prostanoid synthesis
Schildknecht, S., & Ullrich, V. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.10.023 · Cited by 51
Brown, D., Tamás, A., Reglődi, D., & Tizabi, Y. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9468-x · Cited by 51
Self-citationRIFAMPICIN: An antibiotic with brain protective function
Yuluğ, B., Hanoğlu, L., Kılıç, E., & Schabitz, W. R. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.05.007 · Cited by 51
Haddadi, R., Nayebi, A. M., Farajniya, S., Brooshghalan, S. E., & Sharifi, H. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-38 · Cited by 51
Reglődi, D., Tamás, A., Lubics, A., et al. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.05.016 · Cited by 50
Tumor necrosis factor‐α promoter polymorphism is associated with the risk of Parkinson's disease
Wu, Y., Feng, I., Lyu, R., Chang, K., Lin, Y., Chan, H., Hu, F.-J., Lee‐Chen, G., & Chen, C. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30435 · Cited by 50
Tan, Y., Abad, C., Wang, Y., Lopez, R., & Waschek, J. A. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.09.020 · Cited by 49
Ohtaki, H., Satoh, A., Nakamachi, T., et al. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9350-0 · Cited by 49
Xue, X., Liu, H., Qi, L., Li, X., Guo, C., Gong, D., & Qu, H.-Q. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.02.004 · Cited by 49
Siddique, Y. H., Jyoti, S., & Naz, F. (2014) · Journal of Dietary Supplements · doi:10.3109/19390211.2013.859207 · Cited by 49
Reznichenko, L., Kalfon, L., Amit, T., Youdim, M. B. H., & Mandel, S. A. (2010) · Neurodegenerative Diseases · doi:10.1159/000265946 · Cited by 48
Delgado, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02305-7 · Cited by 48
Schneider, J. S., Tinker, J. P., Velson, M. V., & Giardiniere, M. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02036-9 · Cited by 48
Silibinin Attenuates MPP + -Induced Neurotoxicity in the Substantia Nigra In Vivo
Jung, U. J., Jeon, M., Choi, M., & Kim, S. R. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2013.2926 · Cited by 47
Targeting VIP and PACAP Receptor Signalling: New Therapeutic Strategies in Multiple Sclerosis
Tan, Y., & Waschek, J. A. (2011) · ASN NEURO · doi:10.1042/an20110024 · Cited by 47
Rifampicin Attenuates the MPTP-Induced Neurotoxicity in Mouse Brain
Oida, Y., Kitaichi, K., Nakayama, H., Ito, Y., Fujimoto, Y., Shimazawa, M., Nagai, H., & Hara, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.116 · Cited by 47
Rifampicin and Parkinson’s disease
Bi, W., Zhu, L., Jing, X., Liang, Y., & Tao, E. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1156-0 · Cited by 46
Huang, C., Lee, Y., Yang, Y.-C., Kuo, T.-Y., & Huang, N. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2011.12.021 · Cited by 45
Rius, R. A., Guidotti, A., & Costa, E. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00614-8 · Cited by 45
Fang, K., Chen, J.-K., Hung, S.-C., Chen, M.-C., Wu, Y.-T., Wu, T.-J., Lin, H.-I., Chen, C.-H., Cheng, H., Yang, C. S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015299 · Cited by 44
Andreadi, C., Britton, R. G., Patel, K. R., et al. (2014) · Autophagy · doi:10.4161/auto.27593 · Cited by 44
Banki, E., Sosnowska, D., Tucsek, Z., Gautam, T., Tóth, P., Tarantini, S., Tamás, A., Helyes, Z., Reglődi, D., Sonntag, W. E., et al. (2014) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu116 · Cited by 44
Tsuchikawa, D., Nakamachi, T., Tsuchida, M., et al. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9817-2 · Cited by 43
Pradhan, S., & Andreasson, K. I. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.008 · Cited by 43
Reichenstein, M., Rehavi, M., & Pinhasov, A. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9116-0 · Cited by 43
Deguil, J., Jailloux, D., Page, G., Fauconneau, B., Houéto, J., Philippe, M., Jm, M., & Pain, S. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21318 · Cited by 42
Pitaksalee, R., Sanvarinda, Y., Sinchai, T., Sanvarinda, P., Thampithak, A., Jantaratnotai, N., Jariyawat, S., Tuchinda, P., Govitrapong, P., & Sanvarinda, P. (2015) · Neurotoxicity Research · doi:10.1007/s12640-014-9513-9 · Cited by 40
Haddadi, R., Nayebi, A. M., & Brooshghalan, S. E. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.022 · Cited by 40
RIFAMPICIN: AN IMMUNOSUPPRESSANT ?
Dajani, B. M., Canady, M. S., Thompson, J. S., et al. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92390-2 · Cited by 39
Reglődi, D., Lubics, A., Kiss, P., Lengvári, I., Gaszner, B., Tóth, G. K., Hegyi, O., & Tamás, A. (2006) · Neuropeptides · doi:10.1016/j.npep.2006.06.001 · Cited by 39
He, Q., Wang, Y., Lin, W., Zhang, Q., Zhao, J., Liu, F.-T., Tang, Y., Xiao, B., & Wang, J. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9487-7 · Cited by 39
Dányádi, B., Szabadfi, K., Reglődi, D., Mihalik, Á., Danyadi, T., Kovács, Z., Bátai, I. Z., Tamás, A., Kiss, P., Tóth, G. K., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0296-5 · Cited by 39
Peptide-binding GRP78 protects neurons from hypoxia-induced apoptosis
Goldenberg‐Cohen, N., Raiter, A., Gaydar, V., Dratviman‐Storobinsky, O., Goldstein, T., Weizman, A., & Hardy, B. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0678-x · Cited by 38
Drug-induced Hepatitis with Autoimmune Features during Minocycline Therapy.
Abe, M., Furukawa, S., Takayama, S., MlCHITAKA, K., MlNAMI, H., Yamamoto, K., Horiike, N., & Onji, M. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.48 · Cited by 38
Miyamoto, K., Tsumuraya, T., Ohtaki, H., Dohi, K., Satoh, K., Xu, Z., Tanaka, S., Murai, N., Watanabe, J., Sugiyama, K., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0309-4 · Cited by 38
Jing, X., Shi, Q., Bi, W., Zeng, Z., Liang, Y., Wu, X., Xiao, S., Liu, J., Yang, L., & Tao, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092110 · Cited by 38
Metcalfe, M., Huang, Q., & Figueiredo‐Pereira, M. E. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.70 · Cited by 38
Shivers, K., Nikolopoulou, A., Machlovi, S. I., Vallabhajosula, S., & Figueiredo‐Pereira, M. E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.020 · Cited by 38
Li, R., Zheng, N., Liang, T., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.013 · Cited by 38
Resveratrol as a Protective Molecule for Neuroinflammation: A Review of Mechanisms
Renaud, J., & Martinoli, M. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140617101332 · Cited by 37
Self-citationChandran, G., & ., M. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9959-y · Cited by 37
Pirger, Z., Naskar, S., László, Z., Kemenes, G., Reglodi, D., & Kemenes, I. (2014) · The journals of gerontology. Series A, Biological sciences and medical sciences · doi:10.1093/gerona/glu068 · Cited by 37
Self-citationResveratrol and Quercetin Interact to Inhibit Neointimal Hyperplasia in Mice with a Carotid Injury
Khandelwal, A. R., Hebert, V. Y., Kleinedler, J. J., Rogers, L. K., Ullevig, S. L., Asmis, R., Shi, R., & Dugas, T. R. (2012) · Journal of Nutrition · doi:10.3945/jn.112.162628 · Cited by 37
Selkirk, J. V., Nottebaum, L. M., Vana, A. M., Verge, G. M., Mackay, K. B., Stiefel, T. H., Naeve, G. S., Pomeroy, J. E., Petroski, R. E., Moyer, J. A., et al. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04162.x · Cited by 36
Moon, A., Gil, S., Gill, S. E., Chen, P., & Matute‐Bello, G. (2012) · Journal of Inflammation · doi:10.1186/1476-9255-9-31 · Cited by 36
Jung, E. B., & Lee, C. S. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.039 · Cited by 35
Bukovics, P., Czeiter, E., Amrein, K., et al. (2014) · Peptides · doi:10.1016/j.peptides.2014.07.001 · Cited by 35
Reglődi, D., Tamás, A., Lengvári, I., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.072 · Cited by 34
Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Sales, E. M., Ouidja, M. O., Socías, S. B., Celej, M. S., Raisman‐Vozari, R., Papy-García, D., Itri, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544288 · Cited by 34
Self-citationMeesarapee, B., Thampithak, A., Jaisin, Y., et al. (2013) · Phytotherapy Research · doi:10.1002/ptr.5036 · Cited by 33
Watson, M. B., Nobuta, H., Abad, C., Lee, S. K., Bala, N., Zhu, C., Richter, F., Chesselet, M. ‐., & Waschek, J. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.03.002 · Cited by 33
Maturation-dependent apoptotic cell death of oligodendrocytes in myelin-deficient rats
Grinspan, J. B., Coulalaglou, M., Beesley, J., Carpio, D. F., & Scherer, S. S. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981201)54:5 · Cited by 33
MALDI Mass Spectrometry Imaging of 1-Methyl-4-phenylpyridinium (MPP+) in Mouse Brain
Kadar, H., Douaron, G. L., Amar, M., Ferrié, L., Figadère, B., Touboul, D., Brunelle, A., & Raisman‐Vozari, R. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9449-5 · Cited by 33
Self-citationPACAP Stimulates Functional Recovery after Spinal Cord Injury through Axonal Regeneration
Tsuchida, M., Nakamachi, T., Sugiyama, K., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0338-z · Cited by 31
Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
Lü, L., Li, F., & Wang, X. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012035 · Cited by 30
Moser, A., Scholz, J., & Gänsle, A. (1999) · Neuropeptides · doi:10.1054/npep.1999.0768 · Cited by 28
Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro
Wilkins, A., Nikodémová, M., Compston, A., & Duncan, I. D. (2004) · Neuron Glia Biology · doi:10.1017/s1740925x05000104 · Cited by 28
Corbitt, J., Hagerty, T., Fernandez, E., et al. (2002) · Neuropeptides · doi:10.1054/npep.2002.0885 · Cited by 28
Kang, S.-M., More, S. V., Park, J., Kim, B.-W., In, P. J., Yoon, S., & Choi, D. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2013.08.015 · Cited by 27
Wu, S., HSU, L., TU, W., Wang, W., HUANG, Y., Pawlak, C. R., & HO, Y. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.09.013 · Cited by 26
Sandor, B., Fintor, K., Felszeghy, S., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0392-6 · Cited by 26
Protective Effects of PACAP in Excitotoxic Striatal Lesion
Tamás, A., Lubics, A., Lengvári, I., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.083 · Cited by 25
Ortega‐Arellano, H. F., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2013) · Genetics and Molecular Biology · doi:10.1590/s1415-47572013000400020 · Cited by 25
Ma, B., Zhang, M., & Ba, L. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.010 · Cited by 24
Potential of rifamides to inhibit TNF-induced NF-kappaB activation
Pahlevan, A. A. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.3.531 · Cited by 24
Hazama, K., Hayata‐Takano, A., Uetsuki, K., Kasai, A., Encho, N., Shintani, N., Nagayasu, K., Hashimoto, R., Reglődi, D., Miyakawa, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089153 · Cited by 22
Możdżeń, E., Kajta, M., Wąsik, A., et al. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9511-y · Cited by 22
Age-related decrease in cerebrovascular-derived neuroprotective proteins: Effect of acetaminophen
Tripathy, D., Sanchez, A. C., Yin, X., Martinez, J. M., & Grammas, P. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.08.004 · Cited by 20
Vámos, Z., Ivić, I. D., Cséplő, P., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0349-9 · Cited by 19
Use of prokinetics in the preterm infant
Lam, H. S., & Ng, P. C. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283431f2a · Cited by 19
Lin, Y.-P., Chen, T., Tseng, H., Lee, M., & Chen, S.-T. (2012) · Phytochemistry · doi:10.1016/j.phytochem.2012.07.020 · Cited by 17
Maász, G., Pirger, Z., Reglődi, D., et al. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0264-0 · Cited by 17
Induction of serpinb1a by PACAP or NGF is required for PC 12 cells survival after serum withdrawal
Seaborn, T., Ravni, A., Au, R., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12780 · Cited by 17
Németh, A., Szabadfi, K., Fulop, B., et al. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9428-x · Cited by 15
Investigation of PACAP Fragments and Related Peptides in Chronic Retinal Hypoperfusion
Werling, D., Reglődi, D., Kiss, P., et al. (2014) · Journal of Ophthalmology · doi:10.1155/2014/563812 · Cited by 14
Minocycline-induced lupus: a case series.
Porter, D., & Harrison, A. J. (2003) · PubMed · Cited by 14
Antibiotics used in nonbacterial dermatologic conditions
Gordon, R., Mays, R. M., Sambrano, B. L., et al. (2012) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2012.01496.x · Cited by 13
Hua, R., Mao, S., Zhang, Y.-M., et al. (2012) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.issn.1920-8642.2012.04.010 · Cited by 13
Shiwen, Chen, YuanLin, Sun, ., Zhifeng, Zeng, Enxiang, & Tao, T. (2010) · 中国神经再生研究：英文版 · Cited by 12
Resch, J., Albano, R., Liu, X., Hjelmhaug, J., Lobner, D., Baker, D. A., & Choi, S. (2014) · Synapse · doi:10.1002/syn.21772 · Cited by 11
Pawlak, C. R., Chen, F., Wu, F.-Y., & Ho, Y. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.02.010 · Cited by 11
Targeting α-Synuclein in Parkinson's Disease
Kapurniotu, A. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.003 · Cited by 8
Dong, Y., Ning, G., Ewing, A. G., & Heien, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091132 · Cited by 7
Flagged first, then by citations
Cited by
Sorted by citations
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
Doxycycline Inhibits α-Synuclein-Associated Pathologies in Vitro and in Vivo
Dominguez-Meijide, A., Parrales, V., Vasili, E., González-Lizárraga, F., König, A., Lázaro, D. F., Lannuzel, A., Haik, S., Del Bel, E., Chehín, R., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105256 · Cited by 81
Self-citationThe neuroprotective effect of doxycycline on neurodegenerative diseases
Santa-Cecília, F. V., Leite, C. A., Del-Bel, E., & Raisman-Vozari, R. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00015-z · Cited by 73
Self-citationLorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Hong, D., Zhang, C., Wu, W., Lu, X., & Zhang, L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1133546 · Cited by 38
Metadata
- Authors
- Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R.
- Affiliations
- Université du Québec (CA)
- Howard University (US)
- National University of Tucumán (AR)
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 155
- Pages
- 120-148
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2134296216
- Cited by
- 162
- References
- 306
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 15 · 2021: 19 · 2020: 23 · 2019: 21 · 2018: 18 · 2017: 17
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Progress in Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq402658/2012-4)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neuroprotection, polyphenols, antibiotics, neuropeptides, PACAP, alpha-synuclein oligomers, mitochondrial dysfunction, neuroinflammation, oxidative stress, protein misfolding, dopaminergic neurons, anti-apoptotic effects
- MeSH terms
- Neuroprotection, Animals, Anti-Bacterial Agents, Brain, Humans, Neuropeptides, Parkinson Disease, Neuroprotective Agents, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
